Sökning: onr:"swepub:oai:DiVA.org:uu-214322" >
A Randomized Study ...
A Randomized Study of Interferon alpha-2b Versus No Treatment as Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Patients With Relapsed Lymphoma
-
Bosly, Andre (författare)
-
Grigg, Andrew (författare)
-
Holte, Harald (författare)
-
visa fler...
-
Gisselbrecht, Christian (författare)
-
Radford, John (författare)
-
Rossi, Andrea (författare)
-
Lopez-Guillermo, Armando (författare)
-
Trneny, Marek (författare)
-
Sebban, Catherine (författare)
-
- Hagberg, Hans (författare)
- Uppsala universitet,Enheten för onkologi
-
da Costa, Fernando Leal (författare)
-
Colombat, Philippe (författare)
-
Bron, Dominique (författare)
-
Coiffier, Bertrand (författare)
-
visa färre...
-
(creator_code:org_t)
- 2013-10-08
- 2013
- Engelska.
-
Ingår i: The Oncologist. - : Oxford University Press (OUP). - 1083-7159 .- 1549-490X. ; 18:11, s. 1189-1189
- Relaterad länk:
-
https://europepmc.or...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background. Patients with lymphoma who have experienced a first relapse or progression and have disease deemed sensitive to salvage chemotherapy nevertheless have a high likelihood of having a second relapse. To decrease the likelihood of a second relapse after high-dose therapy (HDT) and autologous stem cell transplantation (ASCT), interferon (IFN) alpha-2b was given in a prospective randomized international trial. Methods. In this trial, 221 patients with varying histologic diagnoses (8 small lymphocytic, 37 follicular, 9 mantle, 90 diffuse large B-cell, 20 peripheral T-cell, 3 high-grade B-cell non-Hodgkin lymphoma, and 54 Hodgkin lymphoma) were randomly assigned to receive no further treatment (armA: 117 patients) or IFN alpha-2b, 3 MU three times weekly, for 18 months (arm B: 104 patients). Results. In arm B, 21 patients (20%) did not receive IFN alpha-2b because of early progression or absence of hematologic recovery, 29 patients (28%) completed the 18 months of treatment, and 54 patients (52%) interrupted treatment because of progression (23%) or toxicity (29%). Event-free survival and overall survival were not different between the two arms on an intent-to-treat analysis and also if analysis was restricted to patients who were a live and had not experienced disease progression three months after transplantation. The study was not sufficiently powered to evaluate effects in histologic subtypes. Conclusion. In this trial, post-autograft IFN alpha-2b did not improve outcomes in a heterogeneous group of patients with lymphoma.
Publikations- och innehållstyp
- vet (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Bosly, Andre
-
Grigg, Andrew
-
Holte, Harald
-
Gisselbrecht, Ch ...
-
Radford, John
-
Rossi, Andrea
-
visa fler...
-
Lopez-Guillermo, ...
-
Trneny, Marek
-
Sebban, Catherin ...
-
Hagberg, Hans
-
da Costa, Fernan ...
-
Colombat, Philip ...
-
Bron, Dominique
-
Coiffier, Bertra ...
-
visa färre...
- Artiklar i publikationen
-
The Oncologist
- Av lärosätet
-
Uppsala universitet